Cibinqo®, Dupixent®, Adtralza®, RINVOQ®
Abrocitinib (Cibinqo®), dupilumab (Dupixent®), tralokinumab (Adtralza®) and upadacitinib (RINVOQ®) are available under the High Tech Arrangement. There are two Managed Access Protocols in place for these High Tech medicines for the treatment of atopic dermatitis:
- For adults and adolescents 12 years and older: HSE-Managed Access Protocol for High Tech medicines for the treatment of moderate-to-severe atopic dermatitis.
- For children 6 years to 11 years old: HSE-Managed Access Protocol for dupilumab (Dupixent®) for the treatment of severe atopic dermatitis in children 6 years to 11 years old.
These Managed Access Protocols outline the criteria that must be satisfied in order for a patient to be recommended for reimbursement of abrocitinib, dupilumab, tralokinumab or upadacitinib through the relevant protocol under the High Tech Arrangement.
The prescribing of abrocitinib, dupilumab, tralokinumab and upadacitinib for the treatment of atopic dermatitis is confined to consultant dermatologists who have agreed to the terms of the relevant HSE-Managed Access Protocol and have been approved by the HSE-Medicines Management Programme.
The clinician must submit an online application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.
At the end of June 2023, the HSE had approved 69 prescribers for high tech medicines for atopic dermatitis for adults and adolescents aged 12 years and older. By 30 June 2023, the MMP had reviewed 844 applications for these medicines. Click here for more information.
Copies of the HSE-Managed Access Protocols can be found in the Related Files section below.